JORGE CASTILLO to Proteasome Inhibitors
This is a "connection" page, showing publications JORGE CASTILLO has written about Proteasome Inhibitors.
Connection Strength
1.935
-
CXCR4 mutational status does not impact outcomes in patients with Waldenstr?m macroglobulinemia treated with proteasome inhibitors. Am J Hematol. 2020 04; 95(4):E95-E98.
Score: 0.668
-
Reducing treatment toxicity in Waldenstr?m macroglobulinemia. Expert Opin Drug Saf. 2021 Jun; 20(6):669-676.
Score: 0.180
-
Management of Waldenstr?m macroglobulinemia in 2020. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):372-379.
Score: 0.177
-
EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020 04; 95(4):435-445.
Score: 0.168
-
What is new in the treatment of Waldenstrom macroglobulinemia? Leukemia. 2019 11; 33(11):2555-2562.
Score: 0.164
-
Long survival in patients with Waldenstr?m macroglobulinaemia diagnosed at a young age. Br J Haematol. 2019 05; 185(4):799-802.
Score: 0.154
-
Toward personalized treatment in Waldenstr?m macroglobulinemia. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):365-370.
Score: 0.144
-
Biology, prognosis, and therapy of Waldenstr?m Macroglobulinemia. Cancer Treat Res. 2015; 165:177-95.
Score: 0.118
-
Consensus treatment recommendations from the tenth International Workshop for Waldenstr?m Macroglobulinaemia. Lancet Haematol. 2020 Nov; 7(11):e827-e837.
Score: 0.044
-
Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients. Am J Hematol. 2019 10; 94(10):1132-1140.
Score: 0.040
-
CXCR4 mutations affect presentation and outcomes in patients with Waldenstr?m macroglobulinemia: A systematic review. Expert Rev Hematol. 2019 10; 12(10):873-881.
Score: 0.040
-
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leuk Lymphoma. 2019 01; 60(1):118-123.
Score: 0.037